

ACTA MEDICINAE 4/2013 GYNEKOLOGIE

Kompletní literatura

- 2 Sledování štítné žlázy u těhotných žen**
MUDr. Mgr. Sylvie Špitálníková, Ph.D.
Endokrinologická ambulance Oddělení nukleární medicíny Nemocnice Havlíčkův Brod
- 3 Lidské papilomaviry a možnosti prevence**
MUDr. Daniel Driák, Ph.D.
Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha
- 4 Léčebné modality karcinomu ovaria**
MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno
- 4 Hluboká infiltrující endometrióza**
MUDr. Michael Fanta, Ph.D. Gynekologicko-porodnická klinika VFN a 1. LF UK v Praze
MUDr. Petr Macek, Ph.D., FEBU Urologická klinika VFN a 1. LF UK v Praze
MUDr. Peter Koliba Gynekologicko-porodnická klinika VFN a 1. LF UK v Praze
- 4 Moderní antikoncepční metody, compliance a efektivita**
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě Praha, Katedra gynekologie a porodnictví 3. LF UK Praha, Katedra gynekologie a porodnictví IPVZ Praha
- 5 Biologická léčba v alergologii a imunologii**
prof. MUDr. Ilja Stříž, CSc. Institut klinické a experimentální medicíny, Praha
- 6 Jak může současná klinická imunologie pomoci při řešení recidivujících infekcí**
doc. MUDr. Jaromír Bystrouň, CSc. Oddělení alergologie a klinické imunologie FN Olomouc
- 6 Periferní T-lymfomy (PTCL)**
MUDr. Pavel Klener, Ph.D. 1. interní klinika – hematologie, VFN a 1. LF UK v Praze
Ústav patologické fyziologie 1. LF UK v Praze

Sledování štítné žlázy u těhotných žen

MUDr. Mgr. Sylvie Špitálníková, Ph.D.

Endokrinologická ambulance Oddělení nukleární medicíny Nemocnice Havlíčkův Brod

- 1 Abalovich, M. – Amino, N. – Barbour, L. A. – Cobin, R. H. – De Groot, L. J. – Glinoe, D. – Mandel, S. J. – Stagnaro-Green, A.: Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism*, 2007, 92, s. S1–S47.
- 2 Alexander, K. E. – Marqusee, E. – Lawrence, J. – Jarolim, P. – Fischer, G. A. – Larsen, P. R.: Timing and magnitude of increases in levothyroxin requirements during pregnancy in women with hypothyroidism. *New England Journal of Medicine*, 2004, 351, s. 241–249.
- 3 Alexander, E. K.: Here's to you, baby! A step forward in support of universal screening of thyroid function during pregnancy. *Journal of Clinical Endocrinology and Metabolism*, 2010, 95, s. 1575–1577.
- 4 Benhadi, N. – Wiersinga, W. M. – Reitsma, J. B. – Vrijkotte, T. G. M. – Bonsel, G. J.: Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. *European Journal of Endocrinology*, 2009, 160, s. 985–991.
- 5 De Groot, L. – Abalovich, M. – Alexander, E. K. – Amino, N. – Barbour, L. – Cobin, R. H. – Eastman, C. J. – Lazarus, J. H. – Luton, D. – Mandel, S. J. – Mestman, J. – Rovet, J. – Sullivan, S.: Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society practice guidelines. *Journal of Clinical Endocrinology and Metabolism*, 2012, 97, s. 2543–2565.
- 6 Dosiou, C. – Sanders, G. D. – Araki, S. S. – Crapo, L. M.: Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. *European Journal of Endocrinology*, 2008, 158, s. 841–851.
- 7 Gaertner, R.: Thyroid diseases in pregnancy. *Current Opinion in Obstetrics and Gynecology*, 2009, 21, s. 501–507.
- 8 Haddow, J. E. – Palomaki, G. E. – Allan, W. C. – Williams, J. R. – Knight, G. J. – Gagnon, J. – O'Heir, C. E. – Mitchell, M. L. – Hermos, R. J. – Waisbren, S. E. – Faix, J. D. – Klein, R. Z.: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *New England Journal of Medicine*, 1999, 341, s. 549–555.
- 9 Haddow, J. E. – Knight, G. J. – Palomaki, G. E. – McClain, M. R. – Pulkinen, A. J.: The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. *Journal of Medical Screening*, 2004, 11, s. 170–174.
- 10 Haddow, J. E. – McClain, M. R. – Palomaki, G. E. – Kloza, E. M. – Williams, J.: Screening for thyroid disorders during pregnancy: results of a survey in Maine. *American Journal of Obstetrics and Gynecology*, 2006, 194, s. 471–474.
- 11 Hauerová, D. – Pikner, R. – Topolčan, O. – Mrázová, D. – Holubec, L. – Pecen, L.: Prevalence poruch štítné žlázy u těhotných žen v západočeském regionu ve 2. trimestru těhotenství v roce 2000 – pilotní studie. *Vnitřní Lékařství*, 2002, 48, s. 629–631.
- 12 Horacek, J. – Špitálníková, S. – Dlabacova, B. – Malirova, E. – Vizda, J. – Svilijs, I. – Cepkova, J. – Mc Grath, C. – Maly, J.: Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. *European Journal of Endocrinology*, 2010, 163, s. 645–650.
- 13 Horáček, J. – Jiskra, J. – Límanová, Z. – Springer, D. – Zamrazil, V.: Doporučení pro diagnostiku a léčbu onemocnění štítné žlázy v těhotenství a pro ženy s poruchou fertility. *DMEV*, 2013, 16, s. 38–61.
- 14 Límanová, Z. – Zamrazil, V.: Má být zaveden screening funkčních tyreoidálních onemocnění u dospělých v České republice? *DMEV*, 2004, 7, s. 124–129.
- 15 Mandel, S. J. – Larsen, P. R. – Seely, E. W. – Brent, G. A.: Increased need for thyroxine during pregnancy in women with primary hypothyroidism. *New England Journal of Medicine*, 1990, 323, s. 91–96.
- 16 Mandel, S. J. – Spenser, C. A. – Hollowell, J. G.: Are detection and treatment of thyroid insufficiency in pregnancy feasible? *Thyroid*, 2005, 15, s. 44–53.
- 17 Moleti, M. – Lo Presti, V. P. – Mattina, F. – Mancuso, A. – De Vivo, A. – Giorgianni, G. – Di Bella, B. – Trimarchi, F. – Vermiglio, F.: Gestational thyroid function abnormalities in conditions of mild iodine deficiency: early screening versus continuous monitoring of maternal thyroid status. *European Journal of Endocrinology*, 2009, 160, s. 611–617.
- 18 Negro, R. – Formoso, G. – Mangieri, T. – Pezzarossa, A. – Dazzi, D. – Hassan, H.: Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effect on obstetrical complications. *Journal of Clinical Endocrinology and Metabolism*, 2006, 91, s. 2587–2591.
- 19 Negro, R. – Schwartz, A. – Gismondi, R. – Tinelli, A. – Mangieri, T. – Stagnaro-Green, A.: Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. *Journal of Clinical Endocrinology and Metabolism*, 2010, 95, s. 1699–1707.
- 20 Pop, V. J. – Brouwers, E. P. – Vader, H. L. – Vulsma, T. – Van Baar, A. L. – De Vijlder, J. J.: Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. *Clinical Endocrinology*, 2003, 59, s. 282–288.
- 21 Pop, V. J. – Vulsma, T.: Maternal hypothyroxinaemia during (early) gestation. *The Lancet*, 2005, 365, s. 1604–1606.
- 22 Potlukova, E. – Potluka, O. – Jiskra, J. – Limanova, Z. – Telicka, Z. – Bartakova, J. – Springer, D.: Is age a risk factor for hypothyroidism in pregnancy? An analysis of 5.223 pregnant women. *Journal of Clinical Endocrinology and Metabolism*, 2012, 97, s. 1945–1952.
- 23 Roti, E. – Uberte, E.: Post-partum thyroiditis—a clinical update. *European Journal of Endocrinology*, 2002, 146, s. 275–279.
- 24 Stagnaro-Green, A. – Abalovich, M. – Alexander, E. – Azizi, F. – Mestman, J. – Negro, R. – Nixon, A. – Pearce, E. N. – Soldin, O. P. – Sullivan, S. – Wiersinga, W.: Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid*, 2011, 21, s. 1–45.
- 25 Surks, M. I. – Ortiz, E. – Daniels, G. H. – Sawin, C. T. – Col, N. F. – Cobin, R. H. – Franklyn, J. A. – Hershman, J. M. – Burman, K. D. – Denke, M. A. – Gorman, C. – Cooper, R. S. – Weissman, N. J.: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *Journal of the American Medical Association*, 2004, 291, s. 228–238.
- 26 Špitálníková, S. – Horáček, J. – Antonín, P. – Libus, P.: Výskyt tyreopatií v neselektované populaci těhotných žen jednoho regionu a význam rizikových faktorů pro jejich vznik. *DMEV*, 2011, 14, s. 60–64.
- 27 Thung, S. F. – Funai, E. F. – Grobman, W. A.: The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism. *American Journal of Obstetrics and Gynecology*, 2009, 200, s. 267.e1–267.e7.
- 28 Vaidya, B. – Antony, S. – Bilous, M. – Shields, B. – Drury, J. – Hutchison, S. – Bilous, R.: Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? *Journal of Clinical Endocrinology and Metabolism*, 2007, 92, s. 203–207.
- 29 Vaquero, E. – Lazzarin, N. – De Carolis, C. – Valensise, H. – Moretti, C. – Raminini, C.: Mild thyroid abnormalities and recurrent spontaneous abortion: diagnostic and therapeutic approach. *American Journal of Reproduction and Immunology*, 2000, 43, s. 204–208.

Lidské papilomaviry a možnosti prevence

MUDr. Daniel Driák, Ph.D.

Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha

- 1 **Stanley, M.:** Pathology and epidemiology of HPV infection in females. *Gynecol Oncol*, 117, 2010, s. S5–S10.
- 2 **Trollfors, B.:** Human papillomavirus vaccines: an outsider's point of view. *Expert Rev Vaccines*, 7, 2008, s. 1131–1133.
- 3 **Monk, B. J. – Tewari, K. S.:** The spectrum and clinical sequelae of human papillomavirus infection. *Gynecol Oncol*, 2007, 107, s. S6–S13.
- 4 **Steben, M. – Duarte-Franco, E.:** Human papillomavirus infection: epidemiology and pathophysiology. *Gynecol Oncol*, 2007, 107, s. S2–S5.
- 5 **Hamšíková, E. – Tachezy, R.:** Infekce HPV – epidemiologické a klinické souvislosti. *Farmakoterapie review*, 2007, s. 4–6.
- 6 **Sláma, J.:** Možnosti prevence a principy vakcinace proti HPV. *Farmakoterapie review*, 2007, s. 12–14.
- 7 **Freitag, P.:** *Papillomavírové infekce v gynekologii*. Praha, Triton, 1998, s. 88.
- 8 **Fehrmann, F. – Laimins, L. A.:** Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation. *Oncogene*, 2003, 22, s. 5201–5207.
- 9 **Munger, K. – Howley, P. M.:** Human papillomavirus immortalization and transformation functions. *Virus Res*, 2002, 89, s. 213–228.
- 10 **Bosch, F. X. – Lorincz, A. – Muñoz, N. – Meijer, C. J. L. M. – Shah, K. V.:** The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol*, 2002, 55, s. 244–265.
- 11 **DiSaia, P. J. – Creasman, W. T.:** *Clinical Gynecologic Oncology*. Philadelphia, Mosby Elsevier, 2007, s. 812.
- 12 **Spitzer, M.:** *Human papillomavirus: epidemiology, natural history, and clinical sequelae*. OBG Management 2006, dopl., s. S5–S10.
- 13 **Pluta, M. – Unzeitig, V.:** HPV asociované gynekologické léze v dospělém věku. *Remedia*, 2010, 20, s. 243–247.
- 14 **Cibula, D.:** *HPV vakcinace a screening karcinomu děložního hrdla*. Odborné sympozium, Praha, červen 2009, present.
- 15 **Giuliano A. R.:** Human papillomavirus vaccination in males. *Gynecol Oncol*, 107, 2007, s. S24–S26.
- 16 **Brown, T. J. – Yen-Moore, A. – Tying, S. K.:** An overview of sexually transmitted diseases. Part II. *J Am Acad Dermatol*, 1999, 41, s. 661–677.
- 17 **Tomson, T. T. – Roden, R. B. S. – Wu, T.-C.:** Human papillomavirus vaccines for the prevention and treatment of cervical cancer. *Curr Opin Invest Drugs*, 2004, 5, s. 1247–1261.
- 18 **Robová, H.:** Prekancerózy děložního hrdla. *Mod Gynek Porod*, 2003, 12, s. 627–630.
- 19 **Schwarz, T. F.:** ASO4-adjuvanted human papillomavirus—16/18 vaccination: recent advances in cervical cancer prevention. *Expert Rev Vaccines*, 2008, 7, s. 1465–1473.
- 20 **Freitag, P.:** Profylaktická HPV vakcinace. *Čes Gynek*, 2007, 72, s. 38–41.
- 21 **Tota, J. E. – Chevarie-Davis, M. – Richardson, L. A. – Devries, M. – Franco, E. L.:** Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. *Prev Med*, 2011, dopl., s. S12–S21.
- 22 **Tatti, S.:** *HPV vaccines—a new challenge*. VII. Congress of the ICGI & Ambulatory Gynaecology, Prague, 2006, present.
- 23 **Kane, M. A.:** Preventing cancer with vaccines: progress in the global control of cancer. *Cancer Prev Res (Phila)*, 2012, 5, s. 24–29.
- 24 **Parkin, D. M. – Bray, F.:** Chapter 2: The burden of HPV-related cancers. *Vaccine*, 24, 2006, s. 11–25.
- 25 www.swod.cz.
- 26 **Harper, D. M. – Franco, E. L. – Wheeler, C. – Ferris, D. G. – Jenkins, D. – Schuind, A. – Zahaf, T. – Innis, B. – Naud, P. – De Carvalho, N. S. – Roteli-Martins, C. M. – Teixeira, J. – Blatter, M. M. – Korn, A. P. – Quint, W. – Dubin, G.:** Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet*, 2004, 364, s. 1757–1765.
- 27 **De Vuyst, H. – Clifford, G. M. – Nascimento, M. C., et al.:** Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer*, 124, 2009, s. 1626–1636.
- 28 **Edgren, G. – Sparén, P.:** Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. *Lancet Oncol*, 8, 2007, s. 311–316.
- 29 **Parka, I. U., et al.:** Anal human papillomavirus infection and abnormal anal cytology in women with genital neoplasia. *Gynecol Oncol*, 2009, 114, s. 399–403.
- 30 **Cranston, R. D. – Murphy, R. – Weiss, R. E. – Da Costa, M. – Palefsky, J. – Shoptaw, S. – Gornach, P. M.:** Anal human papillomavirus infection in a street-based sample of drug using HIV-positive men. *Int J STD AIDS*, 23, 2012, s. 195–200.
- 31 **Kačírek, J. – Rob, L. – Robová, H. – Pluta, M.:** Prekancerózy pochvy. *Mod Gynek Porod*, 2003, 12, s. 621–626.
- 32 **Klener, P., et al.:** *Klinická onkologie*. Praha, Galén, 2002.
- 33 **Vosmík, F.:** Onemocnění vyvolaná papilomaviry. In: Štork, J., et al.: *Dermatovenerologie*. Praha, Galén a Karolinum, 2008, s. 122–126.
- 34 **Zhou, J. – Sun, X. Y. – Stenzel, D. I., et al.:** Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. *Virology*, 1991, 185, s. 251–257.
- 35 **Prymula, R.:** *HPV vakcinace – imunogenita a účinnost*. Odborné sympozium, Praha, červen 2009, present.
- 36 **Wakabayashi, M. T. – Da Silva, D. M. – Potkul, R. K. – Kast, W. M.:** Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. *Intervirology*, 2002, 45, s. 300–307.
- 37 SPC Silgard.
- 38 SPC Cervarix.
- 39 **Beran, J.:** Význam nové generace adjuvantního prostředku ve vakcíně proti HPV. *Mod Gynek Porod*, 2007, 16, s. 786–794.
- 40 **Schlecht, N. F. – Burk, R. D. – Nucci-Sack, A., et al.:** Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations. *PLoS One*, 2012, 7, s. 37419. doi:0,1371/journal.pone.00374419.
- 41 **Muñoz, N. – Kjaer, S. K. – Sigurdsson, K. – Iversen, O. E. – Hernandez-Avila, M. – Wheeler, C. M. – Perez, G. – Brown, D. R. – Koutsky, L. A. – Tay, E. H. – Garcia, P. J. – Ault, K. A. – Garland, S. M. – Leodolter, S. – Olsson, S. E. – Tang, G. W. – Ferris, D. G. – Paavonen, J. – Steben, M. – Bosch, F. X. – Dillner, J. – Huh, W. K. – Jaura, E. A. – Kurman, R. J. – Majewski, S. – Myers, E. R. – Villa, L. L. – Taddeo, F. J. – Roberts, C. – Tadesse, A. – Bryan, J. T. – Lupinacci, L. C. – Giacoletti, K. E. – Sings, H. L. – James, M. K. – Hesley, T. M. – Barr, E. – Haupt, R. M.:** Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst*, 2010, 3, 102 (5), s. 325–339.
- 42 www.vakcinace.eu/novinky.
- 43 **Giuliano, A. R. – Palefsky, J. M. – Goldstone, S. – Moreira, E. D. Jr. – Penny, M. E. – Aranda, C. – Vardas, E. – Moi, H. – Jessen, H. – Hillman, R. – Chang, Y. H. – Ferris, D. – Rouleau, D. – Bryan, J. – Marshall, J. B. – Vuocolo, S. – Barr, E. – Radley, D. – Haupt, R. M. – Guris, D.:** Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med*, 2011, 3, 364 (5), s. 401–411.
- 44 **Minárik, J.:** Vakcinace proti HPV z pohledu farmakoekonomiky. *New EU Magazine of Medicine*, 2007, 2, s. 27–30.

Léčebné modality karcinomu ovaria

MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno

- 1 ÚZIS ČR, NOR ČR 2012: *Novotvary*. 2009, ČR.
- 2 Dunder, P.: Prekancerózy endometria, děložní tuby a ovaria: přehled současné problematiky. *Česko-slovenská patologie*, 2012, 1, s. 30–34.
- 3 US Food and Drug Administration: *OvaSure Manufacturer Letter*. 7. 8. 2008. Zveřejněno 1. 9. 2010.
- 4 Fischerová, D. – Zikán, M. – Pinkavová, I., et al.: Racionální předoperační diagnostika benigních a maligních ovariálních nádorů – zobrazovací metody, nádorové markery. *Čes Gynek*, 2012, 77, s. 272–287.
- 5 Ramirez, I. – Chon, H. S. – Apte, S. M.: The role of surgery in the management of epithelial ovarian cancer. *Cancer Control*, 2011, 18, s. 22–30.
- 6 du Bois, A. – Reuss, A. – Pujade-Lauraine, E., et al.: Role of surgical outcome as prognostic factor in advance epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. *Cancer*, 2009, 115, s. 1234–1244.
- 7 Skírnisdóttir, I. – Sorbe, B.: Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. *Int J Oncol*, 2007, 30, s. 727–734.
- 8 Harter, P. – du Bois, A. – Hahmann, M., et al.: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. *Ann Surg Oncol*, 2006, 13, s. 1702–1710.
- 9 Markman, M.: Pharmaceutical management of ovarian cancer: current status. *Drug*, 2008, 68, s. 771–789.
- 10 Modesitt, S. C. – Jazaeri, A. A.: Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. *Expt Opin Pharmacother*, 2007, 8, s. 2293–2305.
- 11 Engelen, M. J. – Snel, B. J. – Schapveld, M., et al.: Long-term morbidity of adjuvant whole abdominal radiotherapy (WAPRT) or chemotherapy for early stage ovaria cancer. *Eur J Cancer*, 2009, 45, s. 1193–1200.
- 12 Burger, R. A. – Brady, M. F. – Bookman, M. A., et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*, 2011, 365, s. 2473–2483.
- 13 Perren, T. J. – Swart, A. M. – Pfisterer, J. N., et al.: A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*, 2011, 365, s. 2484–2496.
- 14 Seimetz, D.: Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (Removab). *J Cancer*, 2011, 2, s. 309–316.

Hluboká infiltruující endometrióza

MUDr. Michael Fanta, Ph.D. Gynekologicko-porodnická klinika VFN a 1. LF UK v Praze

MUDr. Petr Macek, Ph.D., FEBU Urologická klinika VFN a 1. LF UK v Praze

MUDr. Peter Koliba Gynekologicko-porodnická klinika VFN a 1. LF UK v Praze

- 1 Koninckx, P. R. – Martin, D.: Treatment of deeply infiltrating endometriosis. *Curr Opin Obstet Gynecol*, 1994, 6, s. 231–241.
- 2 Fanta, M. – Koliba, P. – Hrušková, H.: Endometrióza. *Česká Gynekologie*, 2012, 77, s. 314–319.
- 3 Munoz, J. L. – Jimenez, J. S. – Tejerizo, A. – Lopez, G. – Duarte, J. – Sanchez Bustos, F.: Rectosigmoid deep infiltrating endometriosis and ureteral involvement with loss of renal function. *Eur J Obstet Gynecol Reprod Biol*, 2012, 162, s. 121–124.
- 4 Kumar, S. – Tiwari, P. – Sharma, P., et al.: Urinary tract endometriosis: Review of 19 cases. *Urology Annals*, 2012, 4, s. 6–12.
- 5 Koninckx, P. R. – Ussia, A. – Adamyan, L. – Wattiez, A. – Donnez, J.: Deep endometriosis: definition, diagnosis, and treatment. *Fertility and Sterility*, 2012, 98, s. 564–571.
- 6 Fauconnier, A. – Chapron, C. – Dubuisson, J. B. – Vieira, M. – Dousset, B. – Bréart, G.: Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis. *Fertil Steril*, 2002, 78 (4), s. 719–726.
- 7 Seracchioli, R. – Mabrouk, M. – Guerrini, M. – Manuzzi, L. – Savelli, L. – Frascà, C. – Venturoli, S.: Dyschezia and posterior deep infiltrating endometriosis: analysis of 360 cases. *J Minim Invasive Gynecol*, 2008, 15 (6), s. 695–699, doi: 10.1016/j.jmig.2008.07.005.

Moderní antikoncepční metody, compliance a efektivita

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě Praha, Katedra gynekologie

a porodnictví 3. LF UK Praha, Katedra gynekologie a porodnictví IPVZ Praha

- 1 Bitzer, J.: Contraceptive compliance—why is contraceptive failure still so frequent? *Therapeutische Umschau Revue thérapeutique*, 2009, 66, s. 137–143.
- 2 Trussell, J.: Contraceptive failure in the United States. *Contraception*, 2011, 83, s. 397–404.
- 3 ČR ÚZIS: Činnost oboru gynekologie a péče o ženy v roce 2010. *Aktuální informace č. 32/2011*, 2011.
- 4 Sitruk-Ware, R. – Nath, A.: Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. *Best practice & research Clinical endocrinology & metabolism*, 2013, 27, s. 13–24.
- 5 Whalen, K. L. – Rose, R.: Estradiol valerate/dienogest: a novel oral contraceptive. *The Annals of Pharmacotherapy*, 2011, 45, s. 1256–1261.
- 6 Druckmann, R.: Profile of the progesterone derivative chlormadinone acetate—pharmacodynamic properties and therapeutic applications. *Contraception*, 2009, 79, s. 272–281.
- 7 Lopez, L. M. – Kaptein, A. A. – Helmerhorst, F. M.: Oral contraceptives containing drospirenone for premenstrual syndrome. *Cochrane database of systematic reviews*, 2012, 2, CD006586.
- 8 Hall, K. S. – Trussell, J.: Types of combined oral contraceptives used by US women. *Contraception*, 2012, 86, s. 659–665.
- 9 Borgelt, L. M. – Kartelů, C. W.: Estradiol valerate/dienogest: a novel combined oral contraceptive. *Clinical therapeutics*, 2012, 34, s. 37–55.
- 10 Sulak, P. J.: Continuous oral contraception: changing times. *Best practice & research Clinical obstetrics & gynaecology*, 2008, 22, s. 355–374.
- 11 de Melo, N. R.: Estrogen-free oral hormonal contraception: benefits of the progestin-only pill. *Women's health*, 2010, 6, s. 721–735.

- 12 Kaunitz, A. M.: Injectable contraception. New and existing options. *Obstetrics and gynecology clinics of North America*, 2000, 27, s. 741–780.
- 13 Bodner, K. – Bodner-Adler, B. – Grunberger, W.: Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users. *Archives of gynecology and obstetrics*, 2011, 283, s. 525–530.
- 14 Roumen, F. J. – Mishell, D. R. Jr.: The contraceptive vaginal ring, Nuva-Ring((R)), a decade after its introduction. *The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception*, 2012, 17, s. 415–427.
- 15 Kaunitz, A. M. – Darney, P. D. – Ross, D., et al.: Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. *Contraception*, 2009, 80, s. 7–17.
- 16 Bigrigg, A. – Evans, M. – Gbolade, B., et al.: Depo Provera. Position paper on clinical use, effectiveness and side effects. *The British journal of family planning*, 1999, 25, s. 69–76.
- 17 Paulen, M. E. – Curtis, K. M.: When can a woman have repeat progestogen-only injectables—depot medroxyprogesterone acetate or norethisterone enantate? *Contraception*, 2009, 80, s. 391–408.
- 18 Draper, B. H. – Morroni, C. – Hoffman, M., et al.: Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. *Cochrane database of systematic reviews*, 2006, CD005214.
- 19 Coukell, A. J. – Balfour, J. A.: Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability. *Druha*, 1998, 55, s. 861–887.
- 20 Funk, S. – Miller, M. M. – Mishell, D. R., et al.: Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. *Contraception*, 2005, 71, s. 319–326.
- 21 Sivin, I. – Schmidt, F.: Effectiveness of IUDs: a review. *Contraception*, 1987, 36, s. 55–84.
- 22 Meirik, O. – Rowe, P. J. – Peregoudov, A., et al.: The frameless copper IUD (GyneFix) and the TCU380A IUD: results of an 8-year multicenter randomized comparative trial. *Contraception*, 2009, 80, s. 133–141.
- 23 Sivin, I. – Stern, J.: Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCU 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). *Fertility and sterility*, 1994, 61, s. 70–77.
- 24 Wildemeersch, D.: New frameless and framed intrauterine devices and systems—an overview. *Contraception*, 2007, 75, s. 82–92.
- 25 Chabbert-Buffet, N. – Ouzounian, S. – Osiris, A. P., et al.: Contraceptive applications of progesterone receptor modulators. *The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception*, 2008, 13, s. 222–230.

Biologická léčba v alergologii a imunologii

prof. MUDr. Ilja Stríž, CSc. Institut klinické a experimentální medicíny, Praha

- 1 Holgate, S. T. – Arshad, H. S. – Roberts, G. C. – Howarth, P. H. – Thurner, P. – Davies, D. E.: A new look at the pathogenesis of asthma. *Clin Sci (Lond)*, 2010, 118, s. 439–450.
- 2 Holgate, S. T.: Innate and adaptive immune responses in asthma. *Nat Med*, 2012, 18, s. 673–683.
- 3 Vasakova, M. – Striz, I. – Slavcev, A. – Jandova, S. – Kolesar, L. – Sulc, J.: Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. *Tissue Antigens*, 2006, 6, s. 229–232.
- 4 Wang, Y. H. – Liu, Y. J.: The IL-17 cytokine family and their role in allergic inflammation. *Curr Opin Immunol*, 2008, 20, s. 697–702.
- 5 Boguniewicz, M. – Martin, R. J. – Martin, D. – Gibson, U. – Celniker, A. – Williams, M. – Leung, D. Y.: The effects of nebulized recombinant interferon-gamma in asthmatic airways. *J Allergy Clin Immunol*, 1995, 95, s. 133–135.
- 6 Bryan, S. A. – O'Connor, B. J. – Matti, S. – Leckie, M. J. – Kanabar, V. – Khan, J. – Warrington, S. J. – Renzetti, L. – Rames, A. – Bock, J. A. – Boyce, M. J. – Hansel, T. T. – Holgate, S. T. – Barnes, P. J.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet*, 2000, 356, s. 2149–2153.
- 7 Nguyen, T. H. – Casale, T. B.: Immune modulation for treatment of allergic disease. *Immunol Rev*, 2012, 242, s. 258–271.
- 8 Striz, I. – Mio, T. – Adachi, Y. – Heires, P. – Robbins, R. A. – Spurzem, J. R. – Illig, M. J. – Romberger, D. J. – Rennard, S. I.: IL-4 induces ICAM-1 expression in human bronchial epithelial cells and potentiates TNF- α . *Am J Physiol*, 1999, 277, s. 58–64.
- 9 Borish, L. C. – Nelson, H. S. – Lanz, M. J. – Claussen, L. – Whitmore, J. B. – Agosti, J. M. – Garrison, L.: Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. *Am J Respir Crit Care Med*, 1999, 160, s. 1816–1823.
- 10 Wenzel, S. – Wilbraham, D. – Fuller, R. – Getz, E. B. – Longphre, M.: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. *Lancet*, 2007, 370, s. 1422–1431.
- 11 Slager, R. E. – Otulana, B. A. – Hawkins, G. A. – Yen, Y. P. – Peters, S. P. – Wenzel, S. E. – Meyers, D. A. – Bleecker, E. R.: IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. *J Allergy Clin Immunol*, 2012, 130, s. 516–522.
- 12 Corren, J. – Lemanske, R. F. – Hanania, N. A. – Korenblat, P. E. – Parssey, M. V. – Arron, J. R. – Harris, J. M. – Scheerens, H. – Wu, L. C. – Su, Z. – Mosesova, S. – Eisner, M. D. – Bohen, S. P. – Matthews, J. G.: Lebrikizumab treatment in adults with asthma. *N Engl J Med*, 2012, 365, s. 1088–1098.
- 13 Chlumsky, J. – Striz, I. – Terl, M. – Vondracek, J.: Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. *J Int Med Res*, 2006, 34, s. 129–139.
- 14 O'Byrne, P. M.: The demise of anti IL-5 for asthma, or not. *Am J Respir Crit Care Med*, 2007, 176, s. 1059–1060.
- 15 Flood-Page, P. – Menzies-Gow, A. – Phipps, S. – Ying, S. – Wangoo, A. – Ludwig, M. S. – Barnes, N. – Robinson, D. – Kay, A. B.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial sub-epithelial basement membrane of mild atopic asthmatics. *J Clin Invest*, 2003, 112, s. 1029–1036.
- 16 Pavord, I. D. – Korn, S. – Howarth, P. – Bleecker, E. R. – Buhl, R. – Keene, O. N. – Ortega, H. – Chanez, P.: Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–659.
- 17 Walsh, G. M.: Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. *Curr Opin Mol Ther*, 2009, 11, s. 329–336.
- 18 Kolbeck, R. – Kozhich, A. – Koike, M. – Peng, L. – Andersson, C. K. – Damschroder, M. M. – Reed, J. L. – Woods, R. – Dall'acqua, A. W. – Stephens, G. L. – Erjefalt, J. S. – Bjermer, L. – Humbles, A. A. – Gossage, D. – Wu, H. – Kiener, P. A. – Spitalny, G. L. – Mackay, C. R. – Molfino, N. A. – Coyle, A. J.: MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. *J Allergy Clin Immunol*, 2010, 125, s. 1344–1353.
- 19 Cheng, G. – Arima, M. – Honda, K. – Hirata, H. – Eda, F. – Yoshida, N. – Fukushima, F. – Ishii, Y. – Fukuda, T.: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. *Am J Respir Crit Care Med*, 2002, 166, s. 409–416.

- 20 Parker, J. M. – Oh, C. K. – LaForce, C. – Miller, S. D. – Pearlman, D. S. – Le, C. – Robbie, G. J. – White, W. I. – White, B. – Molino, N. A.: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. *BMC Pulm Med*, 2011, 11, s. 14.
- 21 Chang, T. W. – Wu, P. C. – Hsu, C. L. – Hung, A. F.: Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. *Adv Immunol*, 2007, 93, s. 63–119.
- 22 Steiss, J. O. – Strohnner, P. – Zimmer, K. P. – Lindemann, H.: Reduction of the total IgE level by omalizumab in children and adolescents. *J Asthma*, 2008, 45, s. 233–236.
- 23 Djukanovic, R. – Wilson, S. J. – Kraft, M. – Jarjour, N. N. – Steel, M. – Chung, K. F. – Bao, W. – Fowler-Taylor, A. – Matthews, J. – Busse, W. W. – Holgate, S. T. – Fahy, J. V.: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. *Am J Respir Crit Care Med*, 2004, 170, s. 583–593.
- 24 van Rensen, E. L. – Evertse, C. E. – van Schadewijk, W. A. – van Wijngaarden, S. – Ayre, G. – Mauad, T. – Hiemstra, P. S. – Sterk, P. J. – Rabe, K. F.: Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. *Allergy*, 2009, 64, s. 72–80.
- 25 Hanf, G. – Brachmann, I. – Kleine-Tebbe, J. – Seybold, J. – Kunkel, G. – Suttrop, N. – Noga, O.: Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. *Allergy*, 2006, 61, s. 1141–1144.
- 26 MacGlashan, D., Jr.: Therapeutic efficacy of omalizumab. *J Allergy Clin Immunol*, 2009, 123, s. 114–115.
- 27 Tarantini, F. – Baiardini, I. – Passalacqua, G. – Braidò, F. – Canonica, G. W.: Asthma treatment: magic bullets which seek their own targets. *Allergy*, 2007, 62, s. 605–610.
- 28 Poole, J. A. – Meng, J. – Reff, M. – Spellman, M. C. – Rosenwasser, L. J.: Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. *J Allergy Clin Immunol*, 2005, 116, s. 780–788.
- 29 Busse, W. W. – Wenzel, S. E. – Meltzer, E. O. – Kerwin, E. M. – Liu, M. C. – Zhang, N. – Chon, Y. – Budelsky, A. L. – Lin, J. – Lin, S. L.: Safety and efficacy of the prostaglandin D(2) receptor antagonist AMG 853 in asthmatic patients. *J Allergy Clin Immunol*, 2013 (v tisku).
- 30 Berry, M. – Brightling, C. – Pavord, I. – Wardlaw, A.: TNF-alpha in asthma. *Curr Opin Pharmacol*, 2007, 7, s. 279–282.
- 31 Tayal, V. – Kalra, B. S.: Cytokines and anti-cytokines as therapeutics—an update. *Eur J Pharmacol*, 2008, 579, s. 1–12.
- 32 Saliu, O. Y. – Sofer, C. – Stein, D. S. – Schwander, S. K. – Wallis, R. S.: Tumor-necrosis-factor blockers: Differential effects on mycobacterial immunity. *J Infect Dis*, 2006, 194, s. 486–492.
- 33 Ramos-Casals, M. – Brito-Zeron, P. – Munoz, S. – Soria, N. – Galiana, D. – Bertolaccini, L. – Cuadrado, M. J. – Khamashta, M. A.: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. *Medicine (Baltimore)*, 2007, 86, s. 242–251.
- 34 Rosenwasser, L. J.: Biologic activities of IL-1 and its role in human disease. *J Allergy Clin Immunol*, 1998, 102, s. 344–350.
- 35 Pazyar, N. – Feily, A. – Yaghoobi, R.: An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. *Curr Clin Pharmacol*, 2012, 7, s. 271–275.
- 36 Mahler, D. A. – Huang, S. – Tabrizi, M. – Bell, G. M.: Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. *Chest*, 2004, 126, s. 926–934.
- 37 Yamagata, T. – Ichinose, M.: Agents against cytokine synthesis or receptors. *Eur J Pharmacol*, 2006, 533, s. 289–301.
- 38 Woodside, D. G. – Vanderslice, P.: Cell adhesion antagonists: Therapeutic potential in asthma and chronic obstructive pulmonary disease. *BioDrugs*, 2008, 22, s. 85–100.

Jak může současná klinická imunologie pomoci při řešení recidivujících infekcí

doc. MUDr. Jaromír Bystron, CSc. Oddělení alergologie a klinické imunologie FN Olomouc

- 1 Bystron, J. – Petru, V. – Krčmová, I., et al.: Účinnost a bezpečnost perorálního bakteriálního imunomodulátoru OLIMUNOVAC u pacientů s častými infekcemi dýchacích cest. *Alergie*, 2011, 13, s. 58–65.
- 2 Bystron, J.: Bakteriální imunomodulátory – současné použití v klinické praxi. *Remedia*, 2010, 20, s. 298–304.
- 3 Bystron, J.: Perorální bakteriální imunomodulátory a medicína založená na důkazech. *Alergie*, 2003, 5, s. 284–290.
- 4 Karaca, N. E. – Gulez, N. – Aksu, G., et al.: Does OM-85 BV prophylaxis trigger autoimmunity in IgA deficient children? *Int Immunopharmacol*, 2011, 11, s. 1747–1751.
- 5 Jeseňák, M. – Rennerová, Z. – Bánovčín, P., et al.: *Recidivující infekce dýchacích cest a imunomodulácia u detí*. Mladá fronta, edice Eskulap, 2012.
- 6 Heřt, J.: *Alternativní medicína a léčitelství. Kritický pohled*. Převzato z: www.sysifos.cz/files/Alternativni_medicina_Hert.pdf.

Periferní T-lymfomy (PTCL)

MUDr. Pavel Klener, Ph.D. 1. interní klinika – hematologie, VFN a 1. LF UK v Praze

Ústav patologické fyziologie 1. LF UK v Praze

- 1 Armitage, J. O. – Vose, J. M. – Weisenburger, D. D.: Towards understanding the peripheral T-cell lymphomas. *Ann Oncol*, 2004, 15, s. 1447–1449.
- 2 Vose, J. M. – Armitage, J. O. – Weisenburger, D. D.: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol*, 2008, 26, s. 4124–4130.
- 3 Delabie, J. – Holte, H. – Vose, J. M. – Ullrich, F. – Jaffe, E. S., et al.: Entropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. *Blood*, 2011, 118, s. 148–155.
- 4 Ferreri, A. J. – Govi, S. – Pileri, S. A.: Hepatosplenic gamma-delta T-cell lymphoma. *Crit Rev Oncol Hematol*, 2012, 83, s. 283–292.
- 5 Dearden, C. E.: T-cell prolymphocytic leukemia. *Clin Lymphoma Myeloma*, 2009, 9, s. 239–243.
- 6 Prince, H. M. – Whittaker, S. – Hoppe, R. T.: How I treat mycosis fungoides and Sezary syndrome. *Blood*, 2009, 114, s. 4337–4353.
- 7 Gill, H. – Liang, R. H. – Tse, E.: Extranodal natural-killer/t-cell lymphoma, nasal type. *Adv Hematol*, 2010, 2010, 627401.

- 8 Suzumiya, J. – Ohshima, K. – Tamura, K. – Karube, K. – Uike, N., et al.: The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. *Ann Oncol*, 2009, 20, s. 715–721.
- 9 Piccaluga, P. P. – Agostinelli, C. – Gazzola, A. – Mannu, C. – Bacci, F., et al.: Prognostic markers in peripheral T-cell lymphoma. *Curr Hematol Malig Rep*, 2010, 5, s. 222–228.
- 10 Savage, K. J. – Ferreri, A. J. – Zinzani, P. L. – Pileri, S. A.: Peripheral T-cell lymphoma—not otherwise specified. *Crit Rev Oncol Hematol*, 2011, 79, s. 321–329.
- 11 Weisenburger, D. D. – Savage, K. J. – Harris, N. L. – Gascoyne, R. D. – Jaffe, E. S., et al.: Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. *Blood*, 2011, 117, s. 3402–3408.
- 12 Grogg, K. L. – Attygalle, A. D. – Macon, W. R. – Remstein, E. D. – Kurtin, P. J., et al.: Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? *Blood*, 2005, 106, s. 1501–1502.
- 13 De Leval, L. – Gisselbrecht, C. – Gaulard, P.: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. *Br J Haematol*, 2010, 148, s. 673–689.
- 14 Mourad, N. – Mounier, N. – Briere, J. – Raffoux, E. – Delmer, A., et al.: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. *Blood*, 2008, 111, s. 4463–4470.
- 15 Ferreri, A. J. – Govi, S. – Pileri, S. A. – Savage, K. J.: Anaplastic large cell lymphoma, ALK-negative. *Crit Rev Oncol Hematol*, 2012.
- 16 Ferreri, A. J. – Govi, S. – Pileri, S. A. – Savage, K. J.: Anaplastic large cell lymphoma, ALK-positive. *Crit Rev Oncol Hematol*, 2012, 83, s. 293–302.
- 17 Savage, K. J. – Harris, N. L. – Vose, J. M. – Ullrich, F. – Jaffe, E. S., et al.: ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood*, 2008, 111, s. 5496–5504.
- 18 Savage, K. J.: Therapies for peripheral T-cell lymphomas. *Hematology Am Soc Hematol Educ Program*, 2011, s. 515–524.
- 19 D'Amore, F. – Relander, T. – Lauritzsen, G. F. – Jantunen, E. – Hagberg, H., et al.: Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. *J Clin Oncol*, 2012, 30, s. 3093–3099.
- 20 Kim, M. K. – Kim, S. – Lee, S. S. – Sym, S. J. – Lee, D. H., et al.: High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. *Ann Hematol*, 2007, 86, s. 435–442.
- 21 Yared, J. – Kimball, A.: The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: A review of the literature and new perspectives. *Cancer Treat Rev*, 2012.
- 22 Procházka, V. – Fáber, E. – Raida, L. – Vondráková, J. – Kučerová, L., et al.: Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2009, 153, s. 63–66.
- 23 Kahl, C. – Leithauser, M. – Wolff, D. – Steiner, B. – Hartung, G., et al.: Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. *Ann Hematol*, 2002, 81, s. 646–650.
- 24 Jaccard, A. – Petit, B. – Girault, S. – Suarez, F. – Gressin, R., et al.: L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. *Ann Oncol*, 2009, 20, s. 110–116.
- 25 Jaccard, A. – Gachard, N. – Marin, B. – Rogez, S. – Audrain, M., et al.: Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. *Blood*, 2011, 117, s. 1834–1839.
- 26 Enblad, G. – Hagberg, H. – Erlanson, M. – Lundin, J. – MacDonald, A. P., et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. *Blood*, 2004, 103, s. 2920–2924.
- 27 Gallamini, A. – Zaja, F. – Patti, C. – Billio, A. – Specchia, M. R., et al.: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. *Blood*, 2007, 110, s. 2316–2323.
- 28 Mahadevan, D. – Unger, J. M. – Spier, C. M. – Persky, D. O. – Young, F., et al.: Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. *Cancer*, 2012.
- 29 Yamaguchi, M. – Kwong, Y. L. – Kim, W. S. – Maeda, Y. – Hashimoto, C., et al.: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *J Clin Oncol*, 2011, 29, s. 4410–4416.
- 30 Zinzani, P. L. – Venturini, F. – Stefoni, V. – Fina, M. – Pellegrini, C., et al.: Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. *Ann Oncol*, 2010, 21, s. 860–863.
- 31 Dang, N. H. – Pro, B. – Hagemester, F. B. – Samaniego, F. – Jones, D., et al.: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. *Br J Haematol*, 2007, 136, s. 439–447.
- 32 Aguiar, B. D.: Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. *Ann Oncol*, 2008, 19, s. 396–397.
- 33 O'Connor, O. A. – Pro, B. – Pinter-Brown, L. – Bartlett, N. – Popplewell, L., et al.: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol*, 2011, 29, s. 1182–1189.
- 34 Mann, B. S. – Johnson, J. R. – Cohen, M. H. – Justice, R. – Pazdur, R.: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. *Oncologist*, 2007, 12, s. 1247–1252.
- 35 Piekarz, R. L. – Frye, R. – Turner, M. – Wright, J. J. – Allen, S. L., et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. *J Clin Oncol*, 2009, 27, s. 5410–5417.
- 36 Piekarz, R. L. – Frye, R. – Prince, H. M. – Kirschbaum, M. H. – Zain, J., et al.: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. *Blood*, 2011, 117, s. 5827–5834.
- 37 Stimson, L. – Wood, V. – Khan, O. – Fotheringham, S. – La Thangue, N. B.: HDAC inhibitor-based therapies and haematological malignancy. *Ann Oncol*, 2009, 20, s. 1293–1302.
- 38 Coiffier, B. – Pro, B. – Prince, H. M. – Foss, F. – Sokol, L., et al.: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. *J Clin Oncol*, 2012, 30, s. 631–636.
- 39 Pro, B. – Advani, R. – Brice, P. – Bartlett, N. L. – Rosenblatt, J. D., et al.: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol*, 2012, 30, s. 2190–2196.
- 40 D'Amore, F. – Radford, J. – Relander, T. – Jerkeman, M. – Tilly, H., et al.: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphoma. *Br J Haematol*, 2010, 150, s. 565–573.
- 41 Yamamoto, K. – Utsunomiya, A. – Tobinai, K. – Tsukasaki, K. – Uike, N., et al.: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. *J Clin Oncol*, 2010, 28, s. 1591–1598.